Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: 3-year interim results from the ongoing Phase 2 open-label extension study

Marc Ferrante  1     Brian G. Feagan  2     Julian Panés  3     Filip Baert  4     Edouard Louis  5     Olivier Dewit  6     Arthur Kaser  7     Weijiang Rachel Duan  8     Dawn Gustafson  9     Xiaomei Liao     Kori Wallace     Jasmina Kalabic     Geert R. D'Haens    
1 University Hospitals Leuven,Leuven,Belgium
2 University of Western Ontario,London,Canada
3 Hospital Clinic de Barcelona,Barcelona,Spain
4 Az Delta,Roeselare,Belgium
5 University Hospital of Liège,Liège,Belgium
6 UCL Saint Luc,Brussels,Belgium
7 University of Cambridge,Cambridge,United Kingdom
8 AbbVie Inc.,North Chicago,United States
9 Abb

Conference
UEG Week 2019

Citation
United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at office@ueg.eu

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing